systemic sclerosis
Conditions
Interventions
After peripheral blood stem cell mobilization and aphereisi with cyclophosphamide 4 g/m2 and G-CSF, CD34+ cells were enriched by using anti-CD34 immunomagnetic beads. Conditioning was performed using
Sponsors
Akashi Koichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A patient aged 16 to 64 who were diagnosed as systemic sclerosis with performance status (ECOG) 0 to 2. a) Within 4 years after onset and modified Rodnan total skin thickness score (mRSS) is 15 or more , and applicable to one of the following organ complication 1) Pulmonary complications: interstitial pneumonia diagnosed by chest X-ray examination or chest CT, and %FVC or %DLCO is less than 80%. 2) Renal complications: systolic blood pressure is 160 mmHg or more or diastolic blood pressure is 110 mmHg or more, urinalysis abnormality (urine protein, urine occult blood, urinary sediment ), microangiopathic hemolytic anemia, or elevated serum creatinine. 3) cardiac complications: reversible heart failure, or arrhythmia (supraventricular, ventricular, AV block), or pericardial effusion b) 1) Involvement of sclerosis to the trunk within 2 years after onset, mRSS is 20 or more, and 2) ESR is 25 mm/1h or more and/or Hb is 11 g/dL or less.
Exclusion criteria
Exclusion criteria: A patient with one of the following severe organ complication, a) Heart: uncontrollable arrhythmia, uncontrollable heart failure, LVEF is less than 50% in cardiac ultrasound examination, moderate or more pulmonary hypertension (mean pulmonary artery pressure is 40 mmHg or more) b) Lung: PaO2 is less than 60 mmHg at room air, %VC is less than 50%. %DLCO is less than 20%. c) Kidney: renal glomerular filtration rate is less than 40 ml/min, serum creatinine is 2 mg/dl or more. d) Uncontrolled malignant neoplasm. e) Uncontrollable infection. f) Cyclophosphamide is used more than 10 g in total.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean change in modified Rodnan skin score at 12 months after transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of 25% improvement in skin score at 12 months. The mean change in forced vital capacity at 12 months. The mean change in serum KL-6 levels at 12 months. Event-free survival. Overall survival Incidence of adverse events. | — |
Countries
Japan
Contacts
Public Contactsachiko kawano
Kyushu University Hospital
Outcome results
None listed